FI942359A0 - Ytantigener av typ I och typ II, vilka hänför sig till Staphylococcus epidermidis - Google Patents

Ytantigener av typ I och typ II, vilka hänför sig till Staphylococcus epidermidis

Info

Publication number
FI942359A0
FI942359A0 FI942359A FI942359A FI942359A0 FI 942359 A0 FI942359 A0 FI 942359A0 FI 942359 A FI942359 A FI 942359A FI 942359 A FI942359 A FI 942359A FI 942359 A0 FI942359 A0 FI 942359A0
Authority
FI
Finland
Prior art keywords
type
epidermidis
surface antigens
staphylococcus epidermidis
serotypes
Prior art date
Application number
FI942359A
Other languages
English (en)
Finnish (fi)
Other versions
FI111336B (sv
FI942359A (sv
Inventor
Ali Ibrahim Fattom
D Craig Wright
Walter W Karakawa
Original Assignee
Univax Biolog Inc
Ali Ibrahim Fattom
D Craig Wright
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univax Biolog Inc, Ali Ibrahim Fattom, D Craig Wright filed Critical Univax Biolog Inc
Publication of FI942359A publication Critical patent/FI942359A/sv
Publication of FI942359A0 publication Critical patent/FI942359A0/sv
Application granted granted Critical
Publication of FI111336B publication Critical patent/FI111336B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI942359A 1991-11-22 1994-05-20 Förfarande för framställning av ett vaccin som innehåller en polysackaridantigen av typ I av Staphylococcus epidermis och ett hyperimmunoglobulin mot antigenen FI111336B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US79625291A 1991-11-22 1991-11-22
US79625291 1991-11-22
PCT/US1992/009784 WO1993009811A1 (en) 1991-11-22 1992-11-20 TYPE I AND TYPE II SURFACE ANTIGENS ASSOCIATED WITH $i(STAPHYLOCOCCUS EPIDERMIDIS)
US9209784 1992-11-20

Publications (3)

Publication Number Publication Date
FI942359A FI942359A (sv) 1994-05-20
FI942359A0 true FI942359A0 (sv) 1994-05-20
FI111336B FI111336B (sv) 2003-07-15

Family

ID=25167715

Family Applications (1)

Application Number Title Priority Date Filing Date
FI942359A FI111336B (sv) 1991-11-22 1994-05-20 Förfarande för framställning av ett vaccin som innehåller en polysackaridantigen av typ I av Staphylococcus epidermis och ett hyperimmunoglobulin mot antigenen

Country Status (12)

Country Link
US (2) US5866140A (sv)
EP (1) EP0648127B1 (sv)
JP (2) JP4087896B2 (sv)
AT (1) ATE237351T1 (sv)
AU (1) AU681573B2 (sv)
CA (1) CA2123811C (sv)
DE (1) DE69233012T2 (sv)
DK (1) DK0648127T3 (sv)
ES (1) ES2198405T3 (sv)
FI (1) FI111336B (sv)
NO (1) NO319013B1 (sv)
WO (1) WO1993009811A1 (sv)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055455A (en) 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
US6632432B1 (en) 1990-10-22 2003-10-14 Henry M. Jackson Foundation For The Advancement Of Military Medicine Directed human immune globulin for the prevention and treatment of staphylococcal infections
US7279162B1 (en) 1990-10-22 2007-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection
US20080139789A1 (en) * 1990-10-22 2008-06-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated Broadly Reactive Opsonic Immunoglobulin for Treating a Pathogenic Coagulase-Negative Staphylococcus Infection
ATE209659T1 (de) * 1994-09-21 2001-12-15 Jackson H M Found Military Med Breit-reaktive opsonische antikörper, die mit gemeinsamen staphylococcus-antigenen reagieren
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US7250494B2 (en) * 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US6824997B1 (en) 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
WO2000012132A1 (en) * 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US6692739B1 (en) 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
ES2321892T3 (es) * 1998-09-14 2009-06-12 Nabi Biopharmaceuticals Composiciones de beta-glucanos e inmunoglobulinas especificas.
US7030101B2 (en) 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of β-glucans and specific antibodies
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
US6703492B1 (en) 1999-11-09 2004-03-09 Smithkline Beecham Corporation Staphylococcus epidermidis nucleic acids and proteins
AU1478301A (en) * 1999-11-09 2001-06-06 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
EP1583517B1 (en) 2002-11-12 2019-06-12 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
WO2004043405A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
ES2738112T3 (es) 2004-04-21 2020-01-20 Brigham & Womens Hospital Inc Péptidos de fijación a la poli-N-acetil glucosamina (PNAG/dPNAG) y procedimientos para el uso de los mismos
KR101505496B1 (ko) * 2004-09-22 2015-03-25 글락소스미스클라인 바이오로지칼즈 에스.에이. 스태필로코쿠스에 대한 예방접종에 사용하기 위한 면역원성 조성물
BRPI0516974A (pt) 2004-10-21 2008-09-30 Wyeth Corp composição imunogênica compreendendo um polipeptìdeo; um método para induzir uma resposta imune contra staphylococcus epidermidis; um método para induzir uma resposta imune contra staphylococcus aureus; um método para a detecção e/ou identificação de staphylococcus epidermidis; um método para a detecção e/ou identificação de anticorpos para staphylococcus epidermidis
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
US20060153857A1 (en) * 2005-01-10 2006-07-13 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection
US20090074755A1 (en) 2005-06-13 2009-03-19 Nabi Biopharmaceuticals Use of panton-valentine leukocidin for treating and preventing staphylococcus infections
CA2655133C (en) 2006-06-12 2018-03-20 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
US7754225B2 (en) * 2006-07-20 2010-07-13 Glaxosmithkline Biologicals S.A. Method of protecting against staphylococcal infection
JP2010535015A (ja) * 2007-07-23 2010-11-18 サノフィ パストゥール リミテッド 免疫原性のポリペプチドおよびモノクローナル抗体
WO2009114520A2 (en) * 2008-03-10 2009-09-17 Pharmain Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
WO2010011284A2 (en) 2008-07-21 2010-01-28 The Brigham And Women's Hospital, Inc. Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
BRPI1015567A2 (pt) 2009-06-22 2021-08-31 Wyeth Llc Composições imunogênicas de antígenos de staphylococcus aureus
NZ597191A (en) 2009-06-22 2013-11-29 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
RS56000B1 (sr) * 2009-10-30 2017-09-29 Glaxosmithkline Biologicals Sa Prečišćavanje stafilokokus aureus tip 5 i tip 8 kapsuliranih saharida
CA2819758A1 (en) 2010-12-03 2012-06-07 Sanofi Pasteur Limited Composition for immunization against streptococcus pneumoniae
CN113730648B (zh) * 2021-09-06 2022-11-01 温州瑞司特生物科技有限公司 结合表皮葡萄球菌的水凝胶及其在治疗创面中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5452794A (en) * 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus
US5097020A (en) * 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
FR2619122B1 (fr) * 1987-08-03 1990-03-09 Pasteur Institut Procede d'obtention de polyosides capsulaires de staphylocoques, polyosides obtenus, applications de ces polyosides et souches pour la mise en oeuvre du procede
US5055455A (en) * 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens

Also Published As

Publication number Publication date
US5866140A (en) 1999-02-02
NO319013B1 (no) 2005-06-06
NO941877D0 (no) 1994-05-19
US5961975A (en) 1999-10-05
JP4353789B2 (ja) 2009-10-28
FI111336B (sv) 2003-07-15
FI942359A (sv) 1994-05-20
ATE237351T1 (de) 2003-05-15
DK0648127T3 (da) 2003-05-19
JP2004155789A (ja) 2004-06-03
NO941877L (no) 1994-06-16
EP0648127B1 (en) 2003-04-16
JP4087896B2 (ja) 2008-05-21
ES2198405T3 (es) 2004-02-01
DE69233012T2 (de) 2003-11-06
CA2123811A1 (en) 1993-05-27
DE69233012D1 (de) 2003-05-22
AU681573B2 (en) 1997-09-04
EP0648127A4 (en) 1995-06-14
JPH07508498A (ja) 1995-09-21
EP0648127A1 (en) 1995-04-19
AU3074792A (en) 1993-06-15
WO1993009811A1 (en) 1993-05-27
CA2123811C (en) 2005-07-05

Similar Documents

Publication Publication Date Title
FI942359A0 (sv) Ytantigener av typ I och typ II, vilka hänför sig till Staphylococcus epidermidis
ATE320265T1 (de) Staphylococcus-antigene und impstoff
ATE188708T1 (de) Antikörperderivate
LV10203A (lv) Panemiens inficesanas ar AIDS noteiksanai olbaltumvielu kompozicija test-komplekts
FI953731A (sv) Förfarande för odling av PRRS-virus och användning därav i vacciner
DK388384D0 (da) Monoklone antistoffer med specifitet for membran-associerede antigene, deres fremstilling og anvendelse
DK0853633T3 (da) Humant monoklonalt antistof imod hepatitis B virus overfladeantigen (HBVsAg)
DK341679A (da) Vaccine mod streptokokker og fremgangsmaade til fremstilling deraf
SE8703225L (sv) Monoklonala antikroppar och peptider anvendbara vid behandling och diagnostisering av hiv-infektioner
DE3175677D1 (en) Polysaccharide antigen from streptococcus and vaccines
ATE107703T1 (de) Bakterielle antigene, antikörper, impfstoffe und deren herstellung.
MX9203629A (es) Composiciones de anticuerpos monoclonales para el tratamiento profilactico o terapeutico de infecciones bacterianas debidas a estreptococos del grupo b.
SE9000333D0 (sv) Monoklonal antikropp
YU22693A (sh) Rekombinantna humana monoklonalna antitela koja neutrališu hiv, za sprečavanje i tretiranje hiv infekcije
DE3686158D1 (de) Impfstoff gegen mastitis.
FI885169A0 (sv) Monoklonal antikropp som förmår känna igen -formen av N-acetylneuraminsyra, antikroppens användning och ett hybridom som producerar dennas
EP0327648A4 (en) HUMAN MONOCLONAL ANTIBODIES AND MEDICINES FOR PROPHYLAXIS AND TREATMENT OF INFECTIOUS DISEASES.
DE3881326D1 (de) Verfahren zur herstellung von paramunitaetsinducern.
ATE134649T1 (de) Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids- verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern
ATE207119T1 (de) Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind
DK621688A (da) Ethylerede avermectiner og praeparater indeholdende disse til behandling og forhindring af parasitinfektioner hos mennesker og dyr
AR004388A1 (es) Anticuerpos que reconocen cadenas de azucares y remedios para enfermedades infecciosas por vih
ZA916313B (en) New use of a monoclonal antibody
DE3381985D1 (de) Verwendung von peptiden.
BG51731A1 (en) Hybridome cellular line mus musculus balb/c, secreting monoclonal antibody against antigenic deternimant, common for the strains hantaan and finnish of the virus of haemorrhagic fever with nephritic syndrome

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A.

Free format text: GLAXOSMITHKLINE BIOLOGICALS S.A.

MA Patent expired